Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunome profiling in prostate cancer: a guide for clinicians

20 Nov 2024

Abstract excerpt

Tumor immune microenvironment (TIME) plays a key role to understand how tumors respond to prostate cancer (PC) therapies and potential mechanisms of resistance. Previous research has suggested that specific genomic aberrations, such as microsatellite instability (MSI) or CDK12 bi-allelic loss can allow PC patients more likely to respond to immune checkpoint inhibitors (ICI) or other immune therapies. However,...

Topics

Join the communities discussing this publication.

Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
Prostate Cancer Treatment and Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39635522
DOI: 10.3389/fimmu.2024.1398109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunome profiling in prostate cancer: a guide for cliniciansPMID 39635522Read ↗

Identification of Prostate Cancer Subtypes Based on Immune Signature Scores in Bulk and Single Cell TranscriptomesSemantic proximity Read ↗

Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy predictionSemantic proximity Read ↗

Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate CancerSemantic proximity Read ↗

Immunogenetics of prostate cancer: a still unexplored field of study.Semantic proximity Read ↗

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological BiomarkersSemantic proximity Read ↗

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological BiomarkersSemantic proximity Read ↗

The Analysis of Tumor Microenvironment of Prostate Cancer Identifies Prognostic SignaturesSemantic proximity Read ↗

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.Semantic proximity Read ↗

Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.Semantic proximity Read ↗

Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistanceSemantic proximity Read ↗

Prioritization of prostate cancer to immune checkpoint therapy by ranking tumors along IFN-γ axis and identification of immune resistance mechanismsSemantic proximity Read ↗

Regulation of prostate cancer progression by the tumor microenvironment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.